Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Cardiology
•
Interventional Cardiology
Do you favor ticagrelor or prasugrel first-line for the treatment of ACS with planned PCI, provided no contraindications to either agent?
Related Questions
When is a reasonable amount of time for patients to be on 90 mg BID of ticagrelor before transitioning to 60 mg BID following PCI?
What neurologic and hemodynamic parameters do you use to determine candidacy for emergent cath lab activation following out of hospital cardiac arrest from VT/VF in patients with NSTEMI after ROSC has been achieved?
For patients presenting with suspected type 1 NSTEMI and atrial fibrillation on anticoagulation, do you favor triple therapy or SAPT with systemic anticoagulation instead while awaiting LHC?
What are your top takeaways from the updated ACS guidelines that will inform changes in clinical practice?
Would acute-onset thrombocytopenia and concern for active bleeding with platelet count below 50,000 prompt you to hold plavix and/or aspirin following PCI that was done 1-2 weeks ago?
What is your preferred duration of aggrastat therapy, and does it differ if patient presented with NSTEMI versus STEMI?
How do you decide between opting for semi-elective outpatient versus inpatient TAVR for patients with severe critical AS?
Do you always give 325mg aspirin if not already loaded with antiplatelets prior to the start of every LHC, even just for diagnostics in the absence of ACS?
What are your preferred femoral vascular closure devices for severely calcified femoral artery vessels following PCI, especially with higher sticks, and why?
How do the results of CREST-2 influence your recommendations on screening for asymptomatic carotid stenosis?
